These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19150342)

  • 1. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon.
    Tani H; Akimitsu N; Fujita O; Matsuda Y; Miyata R; Tsuneda S; Igarashi M; Sekiguchi Y; Noda N
    Biochem Biophys Res Commun; 2009 Feb; 379(4):1054-9. PubMed ID: 19150342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time monitoring of RNA helicase activity using fluorescence resonance energy transfer in vitro.
    Tani H; Fujita O; Furuta A; Matsuda Y; Miyata R; Akimitsu N; Tanaka J; Tsuneda S; Sekiguchi Y; Noda N
    Biochem Biophys Res Commun; 2010 Feb; 393(1):131-6. PubMed ID: 20117090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
    Chen CS; Chiou CT; Chen GS; Chen SC; Hu CY; Chi WK; Chu YD; Hwang LH; Chen PJ; Chen DS; Liaw SH; Chern JW
    J Med Chem; 2009 May; 52(9):2716-23. PubMed ID: 19419203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ELISA for RNA helicase activity: application as an assay of the NS3 helicase of hepatitis C virus.
    Hsu CC; Hwang LH; Huang YW; Chi WK; Chu YD; Chen DS
    Biochem Biophys Res Commun; 1998 Dec; 253(3):594-9. PubMed ID: 9918773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
    Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a high-content screening assay to identify compounds interfering with the formation of the hepatitis C virus replication complex.
    Berke JM; Fenistein D; Pauwels F; Bobbaers R; Lenz O; Lin TI; Krausz E; Fanning G
    J Virol Methods; 2010 May; 165(2):268-76. PubMed ID: 20153373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the NTPase/helicases of hepatitis C and related Flaviviridae viruses.
    Bretner M; Najda A; Podwińska R; Baier A; Paruch K; Lipniacki A; Piasek A; Borowski P; Kulikowski T
    Acta Pol Pharm; 2004 Dec; 61 Suppl():26-8. PubMed ID: 15909930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
    Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein.
    Misialek S; Rajagopalan R; Stevens SK; Beigelman L; Seiwert SD; Kossen K
    Anal Biochem; 2009 Nov; 394(1):138-40. PubMed ID: 19591800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct fluorometric measurement of hepatitis C virus helicase activity.
    Boguszewska-Chachulska AM; Krawczyk M; Stankiewicz A; Gozdek A; Haenni AL; Strokovskaya L
    FEBS Lett; 2004 Jun; 567(2-3):253-8. PubMed ID: 15178332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorometric assay of hepatitis C virus NS3 helicase activity.
    Krawczyk M; Stankiewicz-Drogoń A; Haenni AL; Boguszewska-Chachulska A
    Methods Mol Biol; 2010; 587():211-21. PubMed ID: 20225152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of hepatitis C virus helicase activity using the scintillation proximity assay system.
    Kyono K; Miyashiro M; Taguchi I
    Anal Biochem; 1998 Mar; 257(2):120-6. PubMed ID: 9514793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach.
    Kandil S; Biondaro S; Vlachakis D; Cummins AC; Coluccia A; Berry C; Leyssen P; Neyts J; Brancale A
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2935-7. PubMed ID: 19414257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663.
    Maga G; Gemma S; Fattorusso C; Locatelli GA; Butini S; Persico M; Kukreja G; Romano MP; Chiasserini L; Savini L; Novellino E; Nacci V; Spadari S; Campiani G
    Biochemistry; 2005 Jul; 44(28):9637-44. PubMed ID: 16008349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.
    Najda-Bernatowicz A; Krawczyk M; Stankiewicz-Drogoń A; Bretner M; Boguszewska-Chachulska AM
    Bioorg Med Chem; 2010 Jul; 18(14):5129-36. PubMed ID: 20579888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fluorescence-based screening assay for identification of hepatitis C virus NS3 helicase inhibitors and characterization of their inhibitory mechanism.
    Furuta A; Salam KA; Tani H; Tsuneda S; Sekiguchi Y; Akimitsu N; Noda N
    Methods Mol Biol; 2015; 1259():211-28. PubMed ID: 25579589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase.
    Eltahla AA; Lackovic K; Marquis C; Eden JS; White PA
    J Biomol Screen; 2013 Oct; 18(9):1027-34. PubMed ID: 23708123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Kohara M; Hasegawa T; Nishikawa S
    J Biochem; 2005 Mar; 137(3):339-47. PubMed ID: 15809335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.